CAJ | 학술논문

钠离子／牛磺胆酸共转运多肽（NTCP）是HBV感染的受体。HBV受体的发现为抗HBV新药研发提供了新靶标。阐述了HBV感染研究中遇到的瓶颈、NCTP的发现意义及其表达调节，通过近2年来的研究，发现许多药物可以阻断NTCP的受体功能，进而高效阻断HBV感染，认为HBV进入抑制剂已成为抗HBV新药研发的主流，并且有可能成为未来根治慢性乙型肝炎的策略之一。
납리자／우광담산공전운다태（NTCP）시HBV감염적수체。HBV수체적발현위항HBV신약연발제공료신파표。천술료HBV감염연구중우도적병경、NCTP적발현의의급기표체조절，통과근2년래적연구，발현허다약물가이조단NTCP적수체공능，진이고효조단HBV감염，인위HBV진입억제제이성위항HBV신약연발적주류，병차유가능성위미래근치만성을형간염적책략지일。
Sodium taurocholate cotransporting polypeptide (NTCP)was identified as the receptor for hepatitis B virus (HBV)infection in 2012.The finding of HBV receptor has provided a new target for the development of new anti-HBV drugs.This article describes the bottle-neck of research on HBV infection,as well as the significance of the finding of HBV and its expression regulation.Over the past two years, studies have shown that a variety of agents can block the receptor function of NTCP and then inhibit HBV entry efficiently.The inhibitors of HBV entry have become a major concept in the development of new anti-HBV drugs and may be one of future strategies for radical treatment of chronic hepatitis B.